http://blog.pharmexec.com/2008/05/13/the-dtc-hearings-gleaning-some-nuggets/ The Business of Pharmaceuticals Wed, 08 Feb 2012 14:53:10 -0500 hourly 1 http://blog.pharmexec.com/2008/05/13/the-dtc-hearings-gleaning-some-nuggets/comment-page-1/#comment-1706 DTC-In-Perpsective » Blog Archive » blogspectives - June 2, 2008 Mon, 02 Jun 2008 15:34:48 +0000 http://blog.pharmexec.com/2008/05/13/the-dtc-hearings-gleaning-some-nuggets/#comment-1706 [...] recapping the House hearings of May 9, Pharmaceutical Executive’s Patri ck Clinton comments the hearings were inconclusive as expected. He believes the real issue is whether DTC causes [...] [...] recapping the House hearings of May 9, Pharmaceutical Executive’s Patri ck Clinton comments the hearings were inconclusive as expected. He believes the real issue is whether DTC causes [...]

]]> http://blog.pharmexec.com/2008/05/13/the-dtc-hearings-gleaning-some-nuggets/comment-page-1/#comment-725 Tana Carpenter Wed, 21 May 2008 18:58:07 +0000 http://blog.pharmexec.com/2008/05/13/the-dtc-hearings-gleaning-some-nuggets/#comment-725 The comment 'that drugs shouldn’t be widely promoted until they’ve been on the market long enough to ensure that risks are understood. ' is actually in conflict with most marketing/advertising. A company usually does more advertising when the product first goes on the market. Then, after it's estabilished advertising decreases, until a competitive product appears and the cycle starts again. The comment ‘that drugs shouldn’t be widely promoted until they’ve been on the market long enough to ensure that risks are understood. ‘ is actually in conflict with most marketing/advertising. A company usually does more advertising when the product first goes on the market. Then, after it’s estabilished advertising decreases, until a competitive product appears and the cycle starts again.

]]>